Human iPSC-based skeletal muscle model of LAMA2-related congenital muscular dystrophy.
6 affiliations
- 1The Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
- 2Microbiology, Immunology, and Molecular Genetics, Eli and Edythe Broad Center of Regenerative Medicine, Stem Cell Research, University of California, Los Angeles, Los Angeles, CA, USA.
- 3Division of Pulmonary and Critical Care Medicine, Department of Medicine, Cedars- Sinai Medical Center, Los Angeles, CA, USA.
- 4Division of Gastroenterology and Hepatology, Department of Medicine, Cedars- Sinai Medical Center, Los Angeles, CA, USA.
- 5The Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. [email protected].
- 6Department of Pediatrics, Cedars-Sinai Guerin Children's, Los Angeles, CA, USA. [email protected].
Abstract
Background
Congenital muscular dystrophies (CMDs) are rare, devastating pediatric conditions with no specific treatment or cure. The most common form, LAMA2-related CMD, or LAMA2-CMD (previously known as merosin-deficiency and MDC type 1 A), is caused by myofiber instability from loss of the laminin α2 subunit, a critical extracellular matrix protein in skeletal muscle. Progressive weakness from diffuse skeletal muscle degeneration and fibrosis leads to death in childhood. Animal models significantly enhanced the understanding of LAMA2-CMD and spearheaded innovative rescue strategies. However, limitations of animal models including difficulty recapitulating human muscular dystrophy phenotypes and a lack of validated studies with relevant human tissues have stalled clinical translation. In vitro models of human skeletal muscle exhibiting measurable characteristics of patient disease can significantly improve our ability to study disease mechanisms and further advance therapeutics.Methods
Skeletal muscle progenitor cells (SMPCs), mature myoblasts and 3-dimensional (3D) skeletal muscle tissue were derived from induced pluripotent stem cells of a LAMA2-CMD patient and her unaffected parents as controls. The 3D skeletal muscle constructs were embedded in hydrogel with and without co-seeding with human fibroblasts as supporting cells. Cell fusion, tissue remodeling, contractility and attachment were then analyzed.Results
The 3D skeletal muscle model forms into bundles of multinucleated myotubes, with spontaneous and induced contractions mirroring in vivo muscle tissue. During the skeletal muscle progenitor cell differentiation phase, the LAMA2-CMD neuroectoderm clusters were smaller and less complex than control cases. Despite this, SMPCs were robust and purified at equivalent rates from the patient and control lines. With further differentiation to mature myotubes, LAMA2-CMD cells had reduced cellular fusion compared to control cells. In engineered 3D-skeletal muscle tissues anchored to micropillars, the LAMA2-CMD skeletal muscle demonstrated dystrophic features such as poor attachment, reduced remodeling into compact skeletal muscle bundles, and reduced ability to withstand acetylcholine-induced contractions. The LAMA2-CMD skeletal muscle fibers consistently rupture upon contraction.Conclusion
A patient-derived in vitro model of LAMA2-CMD was established that exhibits a dystrophic phenotype closely resembling the human disease. This platform represents a valuable human tissue model to enhance translational research and therapeutic development efforts for CMDs.
Related
- Tibial Muscular Dystrophy Is a Titinopathy Caused by Mutations in TTN, the Gene Encoding the Giant Skeletal-Muscle Protein Titin
- NuMA1 controls myonuclear motility in striated skeletal muscle through AMPK activity and is impaired in Duchenne muscular dystrophy
- Phenotypic and molecular characterization of INPP5K-related congenital muscular dystrophy in four Egyptian patients
- Image-based assessment of muscle contractile performance in facioscapulohumeral muscular dystrophy: protocol of the MUSCLE+ observational study in the Netherlands
- Muscle strength, quantity and quality and muscle fat quantity and their association with oxidative stress in patients with facioscapulohumeral muscular dystrophy: Effect of antioxidant supplementation
BibTeX
@article{villalba2026human,
title = {{Human iPSC-based skeletal muscle model of LAMA2-related congenital muscular dystrophy.}},
author = {Jaquelyn M Villalba and Andrea Canahui and Francesca I Malit and George Lawless and Vladimir Zhemkov and April D Pyle and Kyu Shik Mun and Sujung Yi and Clive N Svendsen and Michelle R Allen-Sharpley},
journal = {Skeletal muscle},
year = {2026},
month = aug,
doi = {10.1186/s13395-026-00438-1},
url = {https://europepmc.org/article/MED/42972446},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Human iPSC-based skeletal muscle model of LAMA2-related congenital muscular dystrophy.
AU - Jaquelyn M Villalba
AU - Andrea Canahui
AU - Francesca I Malit
AU - George Lawless
AU - Vladimir Zhemkov
AU - April D Pyle
AU - Kyu Shik Mun
AU - Sujung Yi
AU - Clive N Svendsen
AU - Michelle R Allen-Sharpley
PY - 2026
DA - 2026/08/05
JO - Skeletal muscle
DO - 10.1186/s13395-026-00438-1
UR - https://europepmc.org/article/MED/42972446
AB - Background Congenital muscular dystrophies (CMDs) are rare, devastating pediatric conditions with no specific treatment or cure. The most common form, LAMA2-related CMD, or LAMA2-CMD (previously known as merosin-deficiency and MDC type 1 A), is caused by myofiber instability from loss of the laminin α2 subunit, a critical extracellular matrix protein in skeletal muscle. Progressive weakness from diffuse skeletal muscle degeneration and fibrosis leads to death in childhood. Animal models significantly enhanced the understanding of LAMA2-CMD and spearheaded innovative rescue strategies. However, limitations of animal models including difficulty recapitulating human muscular dystrophy phenotypes and a lack of validated studies with relevant human tissues have stalled clinical translation. In vitro models of human skeletal muscle exhibiting measurable characteristics of patient disease can significantly improve our ability to study disease mechanisms and further advance therapeutics.Methods Skeletal muscle progenitor cells (SMPCs), mature myoblasts and 3-dimensional (3D) skeletal muscle tissue were derived from induced pluripotent stem cells of a LAMA2-CMD patient and her unaffected parents as controls. The 3D skeletal muscle constructs were embedded in hydrogel with and without co-seeding with human fibroblasts as supporting cells. Cell fusion, tissue remodeling, contractility and attachment were then analyzed.Results The 3D skeletal muscle model forms into bundles of multinucleated myotubes, with spontaneous and induced contractions mirroring in vivo muscle tissue. During the skeletal muscle progenitor cell differentiation phase, the LAMA2-CMD neuroectoderm clusters were smaller and less complex than control cases. Despite this, SMPCs were robust and purified at equivalent rates from the patient and control lines. With further differentiation to mature myotubes, LAMA2-CMD cells had reduced cellular fusion compared to control cells. In engineered 3D-skeletal muscle tissues anchored to micropillars, the LAMA2-CMD skeletal muscle demonstrated dystrophic features such as poor attachment, reduced remodeling into compact skeletal muscle bundles, and reduced ability to withstand acetylcholine-induced contractions. The LAMA2-CMD skeletal muscle fibers consistently rupture upon contraction.Conclusion A patient-derived in vitro model of LAMA2-CMD was established that exhibits a dystrophic phenotype closely resembling the human disease. This platform represents a valuable human tissue model to enhance translational research and therapeutic development efforts for CMDs.
SN - 2044-5040
ER -